Gastrointestinal (GI) Diseases Therapeutics Market Analysis North America, Asia, Europe, Rest of World (ROW) - US, Germany, France, Japan, China - Size and Forecast 2023-2027

Gastrointestinal (GI) Diseases Therapeutics Market 2023-2027

The global gastrointestinal (GI) diseases therapeutics market size is estimated to grow by USD 17.07 billion at a CAGR of 6.67% between 2022 and 2027. 

Companies in the global gastrointestinal diseases therapeutics market are mainly emphasizing the development of new therapeutics for the treatment of various gastrointestinal-related diseases. Increasing spending on R&D by pharmaceutical and biopharmaceutical companies has supported the development of advanced therapeutics for gastrointestinal diseases. An upsurge in the number of new product launches and product approvals for gastrointestinal disease therapeutics is driving the growth of the gastrointestinal (GI) diseases therapeutics market. For instance, In July 2020, the FDA approved AvsolaTM (Infliximab-axxq) blocker for the treatment of adult and pediatric patients with moderately to severely active Crohn's disease, as well as individuals with moderately to severely active ulcerative colitis who had an insufficient response to traditional therapy. Therefore, new product launches of gastrointestinal disease therapeutics will drive the growth of the market growth during the forecast period.

Technavio has segmented the market into drug class, type, and geography 

• The drug class  is classified into anti-inflammatory and immunosuppressors, acid neutralizers, and others
• The type segment is classified into branded and generics
• The geography segment includes key regions such as North America, Asia, Europe, and Rest of World (ROW)

It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historic data from 2017 to 2021, besides analyzing the current market scenario.

What will be the Size of the Gastrointestinal Diseases Therapeutics Market During the Forecast Period?

To learn more about this report, Request Free Sample

Gastrointestinal Diseases Therapeutics Market Segmentation by Drug Class, Type and Geography 

Drug Class Analysis 

Anti-inflammatory and Immunosuppressors

The market share growth anti-inflammatory and immunosuppressors segment will be significant during the forecast period. Anti-inflammatory and immunosuppressors are the two types of drugs used for the treatment of patients with IBD. The factors contributing to the growth of the anti-inflammatory and immunosuppressors segment of the gastrointestinal (GI) diseases therapeutics market are the rising prevalence of ulcerative colitis and Crohn's disease, the rising focus of vendors on developing biologics, and effective treatment results among patients with IBDs.

Get a glance at the market contribution of various segments View a PDF Sample

The anti-inflammatory and immunosuppression segment was the largest and was valued at USD 20.58 billion in 2017. To reduce the mild to severe pain and inflammation generated due to a wide range of medical conditions, anti-inflammatory drugs are used. Both steroidal and nonsteroidal anti-inflammatory drugs are used to reduce inflammation in the body. On the other hand, immunosuppressors are a class of drugs that are majorly designed to suppress the response to inflammation generated by the immune system. Generally, prescribed immunosuppressors for reducing inflammation among people with gastrointestinal diseasesAzathioprine (Azasan), mercaptopurine (Purinethol), tofacitinib (Xeljanz), and cyclosporine (Gengraf). Pfizer offers XELJANZ (tofacitinib) 10 mg, an immunosuppressor used for the treatment of ulcerative colitis. Tumor necrosis factor (TNF) inhibitors, anti-integrin, anti-interleukin-12, and interleukin-23 therapies are also used in the form of biologics to relieve inflammatory symptoms among people with Crohn's disease and ulcerative colitis. Therefore, the presence of these drugs will boost the growth of the anti-inflammatory and immunosuppressors segment, which will drive the growth of the market during the forecast period.

Type Analysis 

Branded

Branded gastrointestinal disease therapeutics are the medications and treatment options that are developed, manufactured, and marketed by pharmaceutical companies under their brand names. Such products are generally protected by patents and are distinct from generic versions of the same medications. Branded therapeutics frequently deliver unique mechanisms of action, targeting specific pathways or molecules involved in the disease process. Patient fulfillment and commitment to treatment plans are essential for successful disease management. Branded medications may deliver benefits such as suitable dosing regimens or lower side effects, which can enhance patient adherence and have a positive impact on the growth of the gastrointestinal diseases therapeutics market. Therefore, such factors will contribute to the growth of the branded segment, which will drive the growth of the market in focus during the forecast period.

Generic

Generic gastrointestinal disease therapeutics are medications and treatments that are not branded and are available as more reasonable alternatives to their branded counterparts.  The availability of generic versions of branded gastrointestinal disease therapeutics is essential for promoting affordability, expanding patient access to treatment, and reducing the overall cost of healthcare. Generic drugs have played a major role in making crucial medications more accessible to a larger population. Therefore factors such as affordability and therapeutic efficacy will promote the growth of the generics segment, which will fuel the market growth during the forecast period. 

Regional Analysis

For more insights about the market share of various regions View PDF Sample now!

North America is estimated to contribute 40% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. The rising incidence and preponderance of chronic gastrointestinal diseases, increasing healthcare expenditure, and growing preference for therapeutics over surgical procedures are propelling the gastrointestinal (GI) diseases therapeutics market in the region. Also, factors such as the rising emphasis of pharmaceutical and biotechnology companies on R&D to develop novel drugs for IBDs, the growing geriatric population, and the presence of global and regional vendors are also driving the market growth in the region. 

In addition, the increasing prevalence of chronic gastrointestinal diseases, such as IBDs, GERD, ulcerative colitis, and Crohn's disease, drives the demand for therapeutics for treatment. Moreover smoking, intake of certain medicines, and obesity are the major factors that contribute to the development of GERD among people. Uncertainties and delays in providing treatment for chronic gastrointestinal diseases may lead to several medical complications. Therefore the growing demand for various classes of drugs to control gastrointestinal diseases is driving the growth of the gastrointestinal diseases therapeutics market in North America during the forecast period.

In 2020 and early 2021, the outbreak of COVID-19 negatively impacted the gastrointestinal diseases therapeutics market in the region. However, with the outset of vaccination drives and the ease of lockdown restrictions in 2021, the gastrointestinal diseases therapeutics market started recovering along with the normalization of supply chain disruptions. This led to the resumption of postponed gastrointestinal diagnosis and therapeutics, which increased the market growth during the forecast period.

Buy Now Full Report and Discover More

Key Gastrointestinal Diseases Therapeutics Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

Abbott Laboratories - The company offers gastrointestinal disease therapeutics solutions such as medicines for the treatment of irritable bowel syndrome, intrahepatic cholestasis, regulation of the physiological rhythm of the colon, and pancreatic exocrine insufficiency.

• AbbVie Inc.
• AstraZeneca Plc
• Bausch Health Companies Inc.
• Bayer AG
• Biogen Inc.
• Boehringer Ingelheim International GmbH
• Boston Scientific Corp.
• Eisai Co. Ltd.
• Eli Lilly and Co.
• Evoke Pharma Inc.
• GlaxoSmithKline Plc
• Johnson and Johnson
• Merck and Co. Inc.
• Novartis AG
• Olympus Corp.
• Ovesco Endoscopy AG
• Pfizer Inc.
• Takeda Pharmaceutical Co. Ltd.
• UCB SA

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Gastrointestinal Diseases Therapeutics Market: Key Drivers, Trends, Challenges, and Customer Landscape

There are multiple factors influencing market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. 

Key Gastrointestinal Diseases Therapeutics Market Drivers

The increasing incidence of gastrointestinal diseases is notably driving the market growth. The worldwide prevalence of gastrointestinal diseases, including conditions like gallstones, ulcerative colitis, fissures, hemorrhoids, irritable bowel disease (IBD), and gastroesophageal reflux disease (GERD), has witnessed a significant rise. This increase can be attributed to various factors such as unhealthy dietary habits, sedentary lifestyles, stress, food sensitivities, and infections caused by bacteria or viruses. The growing incidence of both chronic and acute gastrointestinal diseases is a cause for concern, as untreated chronic conditions can lead to severe medical complications and disabilities. Among these, IBD is a prevalent gastrointestinal ailment characterized by inflammation of the gastrointestinal tract, necessitating prolonged treatment for prevention and cure. GERD, on the other hand, is a chronic condition affecting individuals across age groups and is associated with complications like erosive esophagitis, esophageal stricture, Barrett's esophagus, dental issues, and asthma.

However, the increasing occurrence of various gastrointestinal diseases has fueled the demand for a range of medications, including antacids, histamine H2-receptor antagonists, laxatives, proton pump inhibitors, and antibiotics, to manage these conditions and mitigate further associated medical complications. This heightened demand for diverse classes of drugs for gastrointestinal disease treatment is a key driver propelling the growth of the global gastrointestinal diseases therapeutics market during the forecast period.

Significant Gastrointestinal Diseases Therapeutics Market Trends

Availability of nutritional therapies is an emerging trend shaping the market growth. Nutritional therapies, encompassing specialized diets and dietary supplements, hold a pivotal role in the management and enhancement of the quality of life for individuals grappling with various gastrointestinal conditions. Some gastrointestinal disorders, such as irritable bowel syndrome (IBS) and celiac disease, exhibit positive responses to dietary alterations. Patients greatly benefit from guidance provided by healthcare professionals and dietitians concerning these dietary adjustments. The availability of resources and certified food products adhering to the low-FODMAP diet is instrumental in supporting patients. For individuals with celiac disease or non-celiac gluten sensitivity, strict adherence to a gluten-free diet is imperative. Access to gluten-free products and clear labeling are crucial for managing these conditions. Omega-3 fatty acids present in fish oil supplements have been researched for their potential advantages in the management of inflammatory bowel disease (IBD).

Furthermore, patients with chronic gastrointestinal diseases face the risk of malnutrition due to nutrient malabsorption. Nutritional therapies, encompassing medical foods and oral nutritional supplements, are vital in addressing malnutrition. The availability of such nutritional therapies is indispensable for the holistic management of gastrointestinal diseases. These therapies can complement pharmaceutical treatments, alleviate symptom severity, and enhance the overall quality of life for patients. This comprehensive approach is expected to drive the growth of the market during the forecast period.

Major Gastrointestinal Diseases Therapeutics Market Challenges

Intense competition from generics and rising patent cliffs a significant challenges hindering the market growth. Gastrointestinal diseases, including conditions like IBD, GERD, gastroenteritis, diarrhea, hemorrhoids, and ulcerative colitis, are typically treated using a range of pharmaceutical interventions, both in the form of small molecules and biologics. Various classes of drugs are employed for the treatment of these conditions, such as acid neutralizers, antibiotics, digestive enzymes, gastrointestinal stimulants, histamine2 blockers, proton pump inhibitors, and antiemetics, among others. Within these drug classes, generic drugs like Omeprazole, Pantoprazole, Nizatidine, Cimetidine, Metoclopramide, Sodium bicarbonate, Sulfasalazine, Balsalazide, Prednisone, and Methotrexate are commonly used due to their cost-effectiveness compared to branded drugs. 

Additionally, the patent cliff, which results in the loss of market exclusivity for approved branded drugs, opens the door for the entry of generic drugs. The increasing number of patent expiries is expected to stimulate the growth of novel biologics and other small molecules in the market. However, the lengthy development process for these new therapies, spanning approximately 6 to 7 years from discovery to commercialization, presents a challenge for pharmaceutical and biotechnology industries involved in gastrointestinal disease therapeutics development which can have a negative impact on the gastrointestinal diseases therapeutics market. Consequently, the patent cliff for blockbuster drugs and the influx of generic alternatives could potentially restrain the growth of the global gastrointestinal diseases therapeutics market to some extent during the forecast period.

Buy Now Full Report and Discover More

Key Gastrointestinal Diseases Therapeutics Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Gastrointestinal Diseases Therapeutics Market Customer Landscape

Segment Overview

The gastrointestinal diseases therapeutics market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027. 

• Drug Class Outlook (USD billion, 2017 - 2027)
  • Anti-inflammatory and immunosuppressors
  • Acid neutralizers
  • Others

• Type Outlook (USD billion, 2017 - 2027)
  • Branded
  • Generics

• Region Outlook (USD billion, 2017 - 2027)
  • North America
    • The U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • Rest of World (ROW)
    • Australia
    • Argentina
    • Brazil  

Gastrointestinal Diseases Therapeutics Market Scope
Report Coverage	Details
Page number	168
Base year	2022
Historic period	2017-2021
Forecast period	2023-2027
Growth momentum & CAGR	Accelerate at a CAGR of 6.67%
Market growth 2023-2027	USD 17.07 billion
Market structure	Fragmented
YoY growth 2022-2023(%)	6.02
Regional analysis	North America, Asia, Europe, and Rest of World (ROW)
Performing market contribution	North America at 40%
Key countries	US, Germany, France, Japan, and China
Competitive landscape	Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks
Key companies profiled	Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Bausch Health Companies Inc., Bayer AG, Biogen Inc., Boehringer Ingelheim International GmbH, Boston Scientific Corp., Eisai Co. Ltd., Eli Lilly and Co., Evoke Pharma Inc., GlaxoSmithKline Plc, Johnson and Johnson, Merck and Co. Inc., Novartis AG, Olympus Corp., Ovesco Endoscopy AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd., and UCB SA
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

View Sample PDF at your Fingertips

What are the Key Data Covered in this Gastrointestinal Diseases Therapeutics Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the gastrointestinal diseases therapeutics market between 2023 and 2027
• Precise estimation of the gastrointestinal diseases therapeutics market size and its contribution to the market in focus on the parent market
• Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
• Companies landscape comparing criticality of inputs and factors of differentiation
• Exclusive Matrix on the company's position and classification
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the market across North America, Asia, Europe, and the Rest of the World (ROW)
• A thorough analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the growth of gastrointestinal diseases therapeutics market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch